相似文献
1
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.
Hepatol Int. 2016 Sep;10(5):681-701. doi: 10.1007/s12072-016-9736-3. Epub 2016 May 26.
2
APASL consensus statements and recommendation on treatment of hepatitis C.
Hepatol Int. 2016 Sep;10(5):702-26. doi: 10.1007/s12072-016-9717-6. Epub 2016 Apr 29.
3
APASL consensus statements and management algorithms for hepatitis C virus infection.
Hepatol Int. 2012 Apr;6(2):409-35. doi: 10.1007/s12072-012-9342-y. Epub 2012 Mar 1.
4
New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.
J Gastroenterol Hepatol. 2007 May;22(5):607-10. doi: 10.1111/j.1440-1746.2007.04969.x.
5
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.
Hepatol Int. 2010 Mar 18;4(2):439-74. doi: 10.1007/s12072-010-9165-7.
6
Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.
J Gastroenterol Hepatol. 2007 May;22(5):615-33. doi: 10.1111/j.1440-1746.2007.04883.x.
7
[Guidelines for the prevention and treatment of hepatitis C (2019 version)].
Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):962-979. doi: 10.3760/cma.j.issn.1007-3418.2019.12.008.
8
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL).
Hepatol Int. 2009 Mar;3(1):269-82. doi: 10.1007/s12072-008-9106-x. Epub 2008 Nov 20.
9
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.
Liver Int. 2005 Jun;25(3):472-89. doi: 10.1111/j.1478-3231.2005.01134.x.
10
Diagnosis, Management And Prevention Of Hepatitis C In Pakistan 2017.
J Ayub Med Coll Abbottabad. 2016 Oct-Dec;28(4 Suppl 1):S839-S882.
引用本文的文献
1
Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia.
Viruses. 2025 May 22;17(6):743. doi: 10.3390/v17060743.
2
CXCL10, SCGN, and H2BC5 as Potential Key Genes Regulated by HCV Infection.
Genes (Basel). 2024 Nov 22;15(12):1502. doi: 10.3390/genes15121502.
3
Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years.
Medicina (Kaunas). 2024 Jul 14;60(7):1132. doi: 10.3390/medicina60071132.
4
Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide.
Kaohsiung J Med Sci. 2024 Feb;40(2):112-118. doi: 10.1002/kjm2.12788. Epub 2023 Nov 27.
5
Chronic Hepatitis C: Acute Exacerbation and Alanine Aminotransferase Flare.
Viruses. 2023 Jan 8;15(1):183. doi: 10.3390/v15010183.
6
Highly Specific and Rapid Detection of Hepatitis C Virus Using RT-LAMP-Coupled CRISPR-Cas12 Assay.
Diagnostics (Basel). 2022 Jun 23;12(7):1524. doi: 10.3390/diagnostics12071524.
7
Transmission networks of hepatitis C virus among HIV/HCV-coinfected patients in Guangdong, China.
Virol J. 2022 Jul 14;19(1):117. doi: 10.1186/s12985-022-01849-4.
8
The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment.
Gut Liver. 2022 Nov 15;16(6):964-975. doi: 10.5009/gnl210416. Epub 2022 Mar 31.
9
Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
World J Gastroenterol. 2022 Jan 14;28(2):263-274. doi: 10.3748/wjg.v28.i2.263.
10
Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting.
Diagnostics (Basel). 2021 Nov 29;11(12):2236. doi: 10.3390/diagnostics11122236.
本文引用的文献
1
New treatments for HCV: Perspective from Asia.
Clin Liver Dis (Hoboken). 2015 Mar 4;5(1):17-21. doi: 10.1002/cld.442. eCollection 2015 Jan.
2
Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
Int J Med Sci. 2016 Apr 10;13(4):310-5. doi: 10.7150/ijms.14953. eCollection 2016.
3
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.
Gastroenterology. 2016 Jul;151(1):130-139.e2. doi: 10.1053/j.gastro.2016.03.036. Epub 2016 Apr 1.
4
Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.
Hepatology. 2016 Jul;64(1):130-7. doi: 10.1002/hep.28535. Epub 2016 Apr 19.
5
Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study.
Curr Drug Targets. 2017;18(7):772-785. doi: 10.2174/1389450117666160208145432.
6
National Trend and Characteristics of Acute Hepatitis C among HIV-Infected Individuals: A Matched Case-Control Study-Taiwan, 2001-2014.
PLoS One. 2015 Oct 6;10(10):e0139687. doi: 10.1371/journal.pone.0139687. eCollection 2015.
7
Successful treatment of HCV-associated cryoglobulinemia with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin: A case report.
J Clin Virol. 2015 Nov;72:66-8. doi: 10.1016/j.jcv.2015.09.003. Epub 2015 Sep 16.
8
APASL consensus statements and management algorithms for hepatitis C virus infection.
Hepatol Int. 2012 Apr;6(2):409-35. doi: 10.1007/s12072-012-9342-y. Epub 2012 Mar 1.
9
Seroprevalence of transfusion-transmissible infectious agents among volunteer blood donors between 2006 and 2012 in Zhejiang, China.
Blood Transfus. 2015 Jul;13(3):401-10. doi: 10.2450/2015.0271-14. Epub 2015 Jun 9.
10
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
Adv Ther. 2015 Jul;32(7):637-49. doi: 10.1007/s12325-015-0221-5. Epub 2015 Jul 9.
Zotero 插件